Prostate cancer is the second most common cancer in men worldwide. ... tumor growth can be slowed down not by inhibiting but by activating the GP130 signaling pathway in prostate cells.

In a significant advancement for prostate cancer research, a first-of-its-kind study led by Emory researchers uncovered how ...

Consequently, research has hypothesized that blocking GP130, thereby disrupting the associated signaling pathway, would inhibit STAT3 activity and, in turn, suppress cancer growth. Surprisingly ...

Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD)..

Background: In the pivotal phase 3 ARASENS trial, patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide in combination with androgen-deprivation therapy (ADT) + ...

A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease. Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S ...

Cite this: Add-On Niraparib May Slow Hormone-Sensitive Metastatic Prostate Cancer - Medscape - June 09, 2025. Comments Commenting is limited to medical professionals.

Proposed roles of active IL6ST signaling in prostate tumorigenesis. Credit: Molecular Cancer (2024). DOI: 10.1186/s12943-024-02114-8 ...